Key points are not available for this paper at this time.
Background: Renal involvement is a rare manifestation of primary Sjögren's syndrome (pSS). The long-term outcome of renal disease in pSS remains poorly understood. Objectives: This observational study aimed to investigate the prevalence, clinical features, and long-term prognosis of renal involvement in pSS. Methods: A multicenter, retrospective longitudinal study was performed using laboratory data and medical chart review. Renal outcome was compared between patients with and without renal involvement, matched for age and sex. Results: Among 1306 pSS patients (mean age, 51 years; 98% female), 28 (2.1%) exhibited renal disease; 15 with tubular interstitial nephritis (TIN), 11 with glomerulonephritis (GN), and one with both. Those with renal involvement showed a higher prevalence of hypergammaglobulinemia, positive Ro, La antibodies, and rheumatoid factor. The prevalence of hematological malignancies was significantly higher in patients with renal involvement (10% vs. 1%, P = 0.020). Sixty-three percent of TIN patients were treated with potassium citrate, while high-dose glucocorticoids were administered to some TIN and GN patients. Over the mean 8.5-year follow-up, 25% of TIN and GN patients experienced significant renal function decline. Renal involvement was identified as a significant risk factor for hematological malignancy. Conclusion: A quarter of pSS patients with renal involvement experienced renal function deterioration. Early detection and proper management through appropriate screening are crucial. Additionally, monitoring for hematological malignancies is recommended in pSS patients with renal involvement. REFERENCES: 1 François H, and Mariette X. Renal involvement in primary Sjögren syndrome. Nat Rev Nephrol. 2016;12(2):82-93. 2 Maripuri S, Grande JP, Osborn TG, Fervenza FC, Matteson EL, Donadio JV, and Hogan MC. Renal involvement in primary Sjögren's syndrome: a clinicopathologic study. Clin J Am Soc Nephrol. 2009;4(9):1423-31. Acknowledgements: NIL. Disclosure of Interests: None declared.
Kim et al. (Sat,) studied this question.